Welcome to our dedicated page for Arcus Biosciences news (Ticker: RCUS), a resource for investors and traders seeking the latest updates and insights on Arcus Biosciences stock.
Arcus Biosciences, Inc. (NASDAQ: RCUS) is a cutting-edge, clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies for cancer treatment. Founded in 2015 by experienced researchers from the biotechnology and pharmaceutical sectors, Arcus is based in the San Francisco Bay Area, a hub for biotechnological innovation.
Arcus Biosciences focuses on leveraging insights in immunology to create new cancer therapeutics. The company is particularly known for its work on the ATP-adenosine pathway, a significant driver of immunosuppression in the tumor microenvironment. Their aim is to optimize small-molecule immuno-oncology product candidates that could revolutionize cancer treatment.
Arcus has a robust product pipeline that includes several promising candidates such as Domvanalimab, Etrumadenant, AB598, and Casdatifan. These drugs target different aspects of the immune system to either modulate cellular processes in cancer or directly combat tumor growth.
Significant achievements include successful clinical trials for treating various types of cancers, including lung, colorectal, and pancreatic cancers. The company operates through a single segment focused on the development and commercialization of its immunotherapies.
Arcus prides itself on maintaining an internal team of highly skilled professionals rather than outsourcing its research and development efforts. This approach ensures the highest quality and innovation in their drug discovery process.
With ongoing partnerships and collaborations, notably with Gilead Sciences, Arcus is well-positioned to bring its innovative therapies to market, providing new hope for patients with cancer.
Arcus Biosciences (NYSE:RCUS) has appointed Richard Markus, M.D., Ph.D. as Chief Medical Officer, effective January 31, 2025, replacing Dimitry Nuyten, M.D., Ph.D. Dr. Markus will oversee the company's clinical development organization and portfolio, which includes seven clinical-stage programs with multiple Phase 3 studies.
The company plans to initiate PEAK-1, its fifth registrational Phase 3 study, in the first half of 2025, evaluating casdatifan plus cabozantinib in clear-cell renal cell carcinoma patients. Dr. Markus brings extensive experience from his 13-year tenure at Amgen, where he served as vice president of global development and oversaw multiple product approvals. Most recently, he founded Dantari, a clinical-stage oncology-focused antibody-drug conjugate company.
Arcus Biosciences (NYSE:RCUS) has granted equity awards to four new employees through its 2020 Inducement Plan. The grants include options to purchase 66,900 shares of common stock at an exercise price of $15.96 per share, which matched the closing price on December 23, 2024. Additionally, the employees received restricted stock units to acquire 33,450 shares of common stock. These awards were approved by the Compensation Committee under the NYSE Listed Company Manual Rule 303A.08 inducement exception.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company specializing in cancer therapeutics, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Terry Rosen, Ph.D., will deliver a presentation on Tuesday, January 14th, 2025, at 3:45pm PT. The presentation will be accessible via live webcast through the 'Investors & Media' section of the company's website, with a replay option available after the event.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on cancer therapies, has granted equity awards to two new employees. The Compensation Committee approved stock options to purchase 7,400 shares at $17.47 per share (the closing price on December 9, 2024) and restricted stock units for 3,700 shares. These equity awards were granted under the Company's 2020 Inducement Plan, which was established under NYSE Listed Company Manual Rule 303A.08's 'inducement exception'.
Arcus Biosciences (NYSE:RCUS) has announced new employment inducement grants approved by its Compensation Committee. The grants include options to purchase 10,000 shares of common stock at an exercise price of $14.56 per share, and restricted stock units to acquire 5,000 shares of common stock. These equity awards were granted to three new employees under the Company's 2020 Inducement Plan, which was established under NYSE Listed Company Manual Rule 303A.08's inducement exception.
Arcus Biosciences (NYSE:RCUS), a clinical-stage biopharmaceutical company developing cancer therapies, has announced its participation in two major investor conferences in December 2024. The company will attend the Evercore 7th Annual HealthCONx Conference in Coral Gables, FL on December 3rd, featuring a fireside chat at 7:55 a.m. ET and one-on-one meetings. Additionally, Arcus will participate in the Citi 2024 Global Healthcare Conference in Miami, FL on December 4th for one-on-one meetings only. Live webcasts and replays will be available on the company's website.
Arcus Biosciences (NYSE:RCUS) announced that its Compensation Committee granted equity awards to four new employees. The grants include options to purchase 14,100 shares of common stock at an exercise price of $17.85 per share, which was the closing price on November 8, 2024. Additionally, the employees received restricted stock units to acquire 7,050 shares. These equity awards were granted under the Company's 2020 Inducement Plan, approved by the Board of Directors in January 2020 under NYSE Listed Company Manual Rule 303A.08's 'inducement exception'.
Arcus Biosciences (NYSE:RCUS) reported promising Q3 2024 results, highlighting significant progress in its cancer therapy pipeline. Key developments include positive data from the Phase 1/1b ARC-20 study of casdatifan, showing a 34% objective response rate in renal cell carcinoma patients. The company announced a new collaboration with AstraZeneca for combination therapy studies. Financial position remains strong with $1.1 billion in cash and equivalents, providing runway into mid-2027. Revenue reached $48 million for Q3 2024, up from $32 million in Q3 2023, though net loss increased to $92 million from $71 million year-over-year.
Arcus Biosciences (NYSE:RCUS) announced positive results from Part 1 of ARC-10 study evaluating domvanalimab plus zimberelimab (DZ) in non-small cell lung cancer patients. The combination demonstrated a 36% reduction in death risk compared to zimberelimab alone, with median overall survival not yet reached versus 24.4 months for zimberelimab. The DZ combination showed improved progression-free survival of 11.5 months versus 6.2 months, and higher objective response rate of 44.7% versus 35%. Treatment-related adverse events leading to discontinuation were lower in the DZ group (10.5%) compared to chemotherapy (23.5%).
Arcus Biosciences (NYSE:RCUS) announced four accepted abstracts for presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Houston, November 6-10, 2024. The key highlight is a late-breaking poster presenting data from ARC-10, including overall survival results for domvanalimab plus zimberelimab in front-line NSCLC patients. The study evaluates this combination versus zimberelimab or chemotherapy in patients with PD-L1-high locally advanced or metastatic NSCLC.
Additionally, an oral presentation will showcase data from an Investigator Sponsored Trial examining domvanalimab and zimberelimab in anti-PD-1 refractory hepatocellular carcinoma. The company will discuss ARC-10 results during its earnings call on November 6, 2024.
FAQ
What is the current stock price of Arcus Biosciences (RCUS)?
What is the market cap of Arcus Biosciences (RCUS)?
What does Arcus Biosciences, Inc. do?
Where is Arcus Biosciences located?
When was Arcus Biosciences founded?
What is the core focus of Arcus Biosciences' research?
What are some of Arcus Biosciences' main products?
What types of cancer does Arcus Biosciences target?
Does Arcus Biosciences outsource its research and development?
With whom does Arcus Biosciences have significant partnerships?
What makes Arcus Biosciences unique?
What is the mission of Arcus Biosciences?
